Two oral drugs — vismodegib, FDA-approved in 2012, and sonidegib, FDA-approved in 2015 — define the hedgehog pathway inhibitor (HPI) class for advanced basal cell carcinoma. A new Dermatology Times feature, published under the headline "Monitoring Safety with Hedgehog Inhibitors in BCC," turns the spotlight on the routine that keeps those patients safely on therapy.

Why the routine is the story

HPI efficacy data settled years ago. The live clinical question is how to keep patients on the drug long enough to see the tumor response without losing them to adverse events first. The article's framing — "monitoring safety" — telegraphs exactly that focus.

Who actually takes this class

Hedgehog inhibitors sit in a narrow lane. They're indicated for adults with locally advanced or metastatic BCC that has recurred after surgery or that surgery can't reasonably address. Most BCCs never reach them. The patient population that does skews older, heavily pretreated, and frequently poor surgical candidates — which is why tolerability shapes every prescribing decision.

What monitoring typically catches

The class carries a documented toxicity profile that dictates the visit schedule rather than the prescription itself. A dermatologist running an HPI patient generally tracks:

• Muscle cramps with creatine kinase (CK) elevations — often dose-limiting
• Dysgeusia, the altered-taste effect that drives downstream appetite and weight loss
• Diffuse alopecia, more a texture change than a pattern loss
• Hepatotoxicity, caught on routine liver function checks
• Embryotoxicity, which mandates a documented pregnancy-status workflow for patients who can become pregnant

A standard cadence pairs a baseline metabolic panel, CK, and pregnancy test (where indicated) with rechecks at two, four, and eight weeks, then monthly intervals. Sonidegib's reference dose of 200 mg daily is frequently stepped down in practice; dose holds and reductions drive most of the day-to-day decision-making.

Why this is a dermatology-only story

Hedgehog inhibitors bridge dermatology and oncology more visibly than almost any other class dermatologists prescribe. The diagnostic label — BCC — belongs to us. The drug lives in the HPI class, and the prescribing often splits: medical oncology handles metastatic disease, dermatology retains the locally advanced cases whose surgical options have closed out. That split is exactly why a monitoring-focused piece in a dermatology title matters. Your patient will almost certainly come back to your exam room between specialist visits with a complaint you should already be able to triage.

The practical question for community dermatologists

So what changes for a general dermatologist who isn't writing the prescription? Plenty. HPI patients cycle between visits to the specialist prescribing the drug and visits to their local dermatologist, and the complaints that surface in your exam room — a sore scalp, a strange taste, sudden cramps — are usually the same toxicities the monitoring routine was built to catch. Recognizing the class profile turns those complaints into early triage calls rather than late referrals.

What's next for this category

Expect Dermatology Times to keep working this beat. Comparative tolerability data between vismodegib and sonidegib remain a moving target, intermittent dosing schedules are gaining traction, and the pipeline of topical and combination approaches may gradually shrink the population that ever needs an oral HPI at all. The class isn't going anywhere — the playbook around it is still being written.